{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:21Z","timestamp":1787015781515,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic recurrent vulvovaginal candidosis (RVVC), defined as three or more episodes of vulvovaginal candidosis per year, significantly impairs quality of life (QoL) and sexual health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The primary objective of this study was to assess health\u2010related QoL in women with RVVC using validated questionnaires before and after treatment. The secondary objective was to analyse the effect of RVVC on women's sexual health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients\/Methods<\/jats:title>\n                    <jats:p>\n                      This was a sub\u2010analysis of a randomised, controlled, double\u2010blinded study titled \u2018A phase IIb\/III, parallel\u2010arm, randomized, active\u2010controlled, double\u2010blind, double\u2010dummy, multicenter, non\u2010inferiority study in patients with recurrent vulvovaginal candidosis to compare the clinical efficacy, safety and tolerability of topically administered ProF\u2010001 (Candiplus\u00ae) to oral fluconazole\n                      <jats:italic>,<\/jats:italic>\n                      which was conducted at 35 study sites in Austria, Poland and Slovakia. QoL was assessed using the European Quality of Life (EQ) five\u2010dimension five\u2010level scale (EQ\u20105D\u20105L) and visual analogue scale (EQ\u2010VAS) questionnaires, followed by specific questions regarding sexuality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 2019 to 2021, 360 of 432 (83.3%) women with RVVC had accomplished a 6\u2010months maintenance treatment and were enrolled in this sub\u2010analysis. The EQ\u20105D\u20105L and EQ\u2010VAS scores demonstrated improved QoL in 137 (65.2%) and 159 (75.4%) women after 6\u2009months of maintenance treatment. Each individual aspect of sexual health significantly improved (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.05). A reduction in pain frequency during or after sexual intercourse in the 6\u2010month period occurred in 124 (66.3%) women.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Women with RVVC had high QoL and sexual health impairment; however, a 6\u2010months maintenance treatment resulted in effective improvement in QoL and sexual health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/myc.13602","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T23:26:42Z","timestamp":1683329202000},"page":"767-773","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Quality of life in women with chronic recurrent vulvovaginal candidosis: A sub\u2010analysis of the prospective multicentre phase\n                    <scp>IIb<\/scp>\n                    \/\n                    <scp>III<\/scp>\n                    Prof\u2010001 study"],"prefix":"10.1111","volume":"66","author":[{"given":"Andrea","family":"Lietz","sequence":"first","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-0097","authenticated-orcid":false,"given":"Fanny","family":"Eckel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Obstetrics and Feto\u2010maternal Medicine Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Obstetrics and Feto\u2010maternal Medicine Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Noe\u2010Letschnig","sequence":"additional","affiliation":[{"name":"ProFem GmbH  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-9052","authenticated-orcid":false,"given":"Alex","family":"Farr","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Obstetrics and Feto\u2010maternal Medicine Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-010-0096-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13248"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"e_1_2_8_5_1","unstructured":"CDC.Sexually Transmitted Infections Treatment Guidelines 2021 \u2010 Vulvovaginal Candidiasis (VVC) https:\/\/www.cdc.gov\/std\/treatment\u2010guidelines\/candidiasis.htm(accessed 8 December2022)."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033114"},{"issue":"613","key":"e_1_2_8_7_1","first-page":"e1","article-title":"Individualized decreasing\u2010dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial)","volume":"199","author":"Donders G","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.4274\/jtgga.galenos.2019.2019.0077"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.74.5.334"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S176851"},{"key":"e_1_2_8_11_1","first-page":"5","article-title":"Treatment of vulvovaginal candidiasis: a review of the literature","volume":"24","author":"Dovnik A","year":"2015","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)80001-X"},{"key":"e_1_2_8_13_1","volume-title":"Berek & Novak's gynecology","author":"Berek JS","year":"2012"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-019-0748-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60917-9"},{"issue":"38","key":"e_1_2_8_16_1","first-page":"e1","article-title":"Identification of novel mechanisms involved in generating localized vulvodynia pain","volume":"213","author":"Falsetta ML","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460320.95267.5d"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002613"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.09.030"},{"key":"e_1_2_8_20_1","unstructured":"World Health Organization.WHOQOL: Measuring Quality of Life.https:\/\/www.who.int\/healthinfo\/survey\/whoqol\u2010qualityoflife\/en\/(accessed 8 December 2022)."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05228-3"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0470-2"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-169"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01235.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/01674820601168176"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:44:19Z","timestamp":1692236659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.13602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/myc.13602"],"URL":"https:\/\/doi.org\/10.1111\/myc.13602","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"2023-01-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}